Bayer HealthCare

Bayer CEO Marijn Dekkers

8. Bayer HealthCare
2013 revenue: 
€18.924 billion ($25.969 billion)
2012 revenue: €18.604 billion ($24.300 billion)

Bayer's sitting pretty as far as its pharma lineup goes. The German company counts blood thinner Xarelto and eye med Eylea among its revenue-makers, and those make up a pretty big one-two combo. Together, the pair helped Bayer's pharma sales balloon 9.4% in 2013, reaching €11.2 billion; along with cancer therapies Stivarga and Xofigo and pulmonary hypertension treatment Adempas, they posted a combined €1.5 billion in 2013 sales.

Bayer expects big things from those drugs going forward, too: The company recently raised their sales forecast, and it now projects the pack of new sellers will together turn in peak sales of €7.5 billion ($10.3 billion) or more. But that's not to say the company won't get growth from standbys; clotting med and blockbuster orphan drug Kogenate, for one, put up a 6.4% sales hike in 2013.

As CEO Marijn Dekkers noted when announcing the year's financial results, Bayer's consumer care unit also saw "positive sales development," growing by 3.2% to hit €7.7 billion. The company has been pursuing an expansion strategy focusing on bolt-on acquisitions, most recently nabbing Chinese OTC maker Dihon Pharmaceutical Group. That pickup should put Bayer in a leading position in China's OTC industry, the company said.

And there could be even bigger deals on the way. Bayer is reportedly among the companies eyeing Merck's ($MRK) consumer health unit, which could draw bids of up to $12 billion. Dekkers said late last year that the company is also committed to expanding its animal health division, and some speculated last December that it may be interested in Novartis' ($NVS) unit, which is rumored to be up for grabs as the result of a company-wide review.

-- Carly Helfand (email | Twitter)

For more:
Special Reports: Top Pharma Companies by 2012 Revenues - Bayer HealthCare | Top 15 Drug Launch Superstars - Eylea - Xarelto
Once again, Bayer's new drugs power pharma sales upward
Bayer's new drugs shine, fueling 5.5% pharma growth

Bayer HealthCare
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.